ストックスクリーナーアプリを入手
1.95
8.45%
-0.18
アフターアワーズ：
2.00
0.05
+2.56%
Gain Therapeutics Inc (GANX) 最新ニュース
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Finance
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
GAIN THERAPEUTICS: A Microcap Stock to Love - substack.com
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain - Yahoo Finance
Does Gain Therapeutics Inc (NASDAQ: GANX) Still Need To Convince Analysts? - Stocks Register
2025 Pipeline Report: The Edge of Greatness? - Pharmaceutical Executive
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Travere Therapeutics Delivers Over 180% Gain In 6 Months - Nasdaq
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
Novartis to Buy Anthos Therapeutics for $925 Million - Bloomberg
Daily Progress: Wearable Devices Ltd (WLDS) Gain 1.76, Closing at 0.95 - The Dwinnex
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research - The Globe and Mail
Janux Therapeutics Inc (NASDAQ: JANX) Gain Of 80.16% Compared To 52-Week Low; YTD Fall -26.47% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
reAlpha Tech Corp (NASDAQ: AIRE) Gain Of 70.56% Compared To 52-Week Low; YTD Fall -37.72% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Sacks Parente Golf Inc (NASDAQ: SPGC): Can The Stock Still Lose Despite An 38.15% YTD Gain? - Marketing Sentinel
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Can you now get a good deal on PTC Therapeutics Inc’s shares? - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Philip Morris Q4: Earnings Beat, Smoke-Free Sales Gain Ground & More - Yahoo Finance
Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease - Nasdaq
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next? - Defense World
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval - Yahoo Finance
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Gain Therapeutics To Participate in Upcoming Investor Conferences - The Manila Times
Gain Therapeutics, Inc. Announces Upcoming Presentations at BIO CEO & Investor Conference and Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
Biotech Spotlight: Gain Therapeutics Takes Center Stage at Two Major Investor Conferences - StockTitan
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Closing Figures Unveiled: Canada Goose Holdings Inc (GOOS) Gain 1.05, Closes at 10.57 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
Gene editing companies to gain from FDA’s platform designation update - BioCentury
How to interpret Omega Therapeutics Inc (OMGA)’s stock chart patterns - US Post News
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Closing Figures Unveiled: Ondas Holdings Inc (ONDS) Gain 3.55, Closes at 1.75 - The Dwinnex
2025's 10 Best-Performing Stocks - U.S News & World Report Money
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Digihost Technology Inc.'s (CVE:DGHI) 28% gain last week benefited both individual investors who own 58% as well as insiders - Yahoo Finance
Amentum Holdings Inc (AMTM) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Takeda makes waves again with CEO pick - BioCentury
UiPath Inc (PATH) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - Morningstar
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach - Yahoo Finance
Sector Update: Health Care Stocks Gain Late Afternoon -January 27, 2025 at 04:04 pm EST - Marketscreener.com
Nvidia Shares Tumbles as Japanese Rivals Gain Ground in AI Chips - Yahoo Finance
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):